Novel octapeptin antibiotics targeting extremely drug resistant 'superbugs'

新型八肽抗生素针对耐药性极强的“超级细菌”

• 批准号: nhmrc : 1128891
• 负责人: Dr Tony Velkov
• 金额: $ 64.73万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-octapeptin-antibiotics-resistant-superbugs/948295
• 关键词: Novel; octapeptin; antibiotics; targeting; extremely

The World Health Organization (WHO) has identified antimicrobial resistance as one of the three greatest threats to human health. Many clinicians worldwide have already been confronted with the reality of infections caused by extremely drug resistant (XDR) bacterial 'superbugs' resistant to all available antibiotics. This project aims to develop safe and efficacious octapeptin antibiotics for the treatment of life-threatening infections caused by problematic XDR ‘superbugs'.

世界卫生组织（世卫组织）已确定抗菌素耐药性是对人类健康的三大威胁之一。世界各地的许多临床医生已经面临着由对所有现有抗生素都具有耐药性的极端耐药（XDR）细菌“超级细菌”引起的感染的现实。该项目旨在开发安全有效的octapeptin抗生素，用于治疗由有问题的XDR“超级细菌”引起的危及生命的感染。